2 weeks Ago By ABMN Staff
Shares of Pfizer Inc. ( NYSE:PFE – Get Free Report ) have been assigned an average rating of “Moderate Buy” from the fifteen brokerages that are covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company.
The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $34.54. A number of analysts have weighed in on the stock.
StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th.
Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, September 16th. Wells Fargo & Company increased their price target on Pfizer from $28.
00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.
00 to $34.00 in a research note on Wednesday, August 7th. View Our Latest Stock Analysis on Pfizer Pfizer Trading Up 0.
5 % Pfizer ( NYSE:PFE – Get Free Report ) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.
46 by $0.14. Pfizer had a positive return on equity of 8.
42% and a negative net margin of 4.66%. The business had revenue of $13.
28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the business posted $0.
67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis.
As a group, equities analysts forecast that Pfizer will post 2.66 EPS for the current year. Institutional Trading of Pfizer A number of hedge funds and other institutional investors have recently bought and sold shares of PFE.
Olistico Wealth LLC acquired a new stake in shares of Pfizer in the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer in the second quarter worth approximately $29,000. Quarry LP bought a new position in shares of Pfizer in the second quarter valued at approximately $31,000.
Creekmur Asset Management LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $32,000. Finally, Trivant Custom Portfolio Group LLC grew its holdings in Pfizer by 100.0% during the first quarter.
Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.
Pfizer Company Profile ( Get Free Report Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. See Also Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.
com's FREE daily email newsletter ..
